BioWorld

July 20, 2005

$525M Gets Emtriva Interest From Emory For Gilead, Royalty Pharma

Gilead Sciences Inc. and Royalty Pharma bought out Emory University's royalty interest in emtricitabine - or Emtriva - for $525 million. (BioWorld Today) Read More

After Long Wait, Crawford Confirmed As Head Of FDA

Arakis Providing Exit Via £106.5M Sosei Acquisition

Ilypsa's Series B Adds $36M For Renal Disease Products

Correction

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...